Arthralgia During Anastrozole Therapy for Breast Cancer

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Early Breast Cancer

Treatments: Drug: Anastrozole

Study type: Interventional

Funder types: Industry

Identifiers

NCT00323479

D5392L00013

2005-00-5441-19 EUDRACT number

Details and patient eligibility

About

The purpose of this study is to describe the joint symptoms and structural joint changes under anastrozole as adjuvant treatment in postmenopausal women with early breast cancer.

Enrollment: 114 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole
• WHO performance status 0, 1 or 2
• Provision of written informed consent

Exclusion criteria

• Recurrence of breast cancer, inflammatory rheumatism
• treatment by chondromodulator, oral glucocorticoid, aromatase inhibitor, anti estrogen, Herceptin
• Diabetes treated by insulin
• Severe renal or hepatic disease
• Known hypersensitivity to anastrozole

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)